Key highlights
- Novo Nordisk invests €432 million in Athlone, Ireland facility.
- The expansion focuses on GLP-1 oral treatments.
- 500 construction jobs will be created.
- Completion is expected between 2027 and 2028.
Investment Overview
Novo Nordisk has announced a €432 million investment in its Monksland facility in Athlone, Ireland. This expansion aims to increase manufacturing capacity for GLP-1 oral treatments.
Strategic Importance
The investment enhances Novo Nordisk's manufacturing capabilities for oral products and strengthens Ireland's role as a key hub for servicing markets outside the US. The project will upgrade and retrofit the existing facility.
Job Creation and Timeline
The expansion will create up to 500 construction jobs. The construction projects have already begun and are expected to be completed gradually from the end of 2027 through 2028.
Current Operations
The existing 260 employees at the Athlone plant will focus on delivering high-quality oral treatments efficiently and sustainably.
